Oxford University Press

SHERPA: Yellow

People

  1. Rathkopf
    Rathkopf
  2. Scher
    Scher
  3. Slovin
    Slovin
  4. Abida
    Abida
  5. Morris
    Morris
  6. Autio
    Autio
  7. Carver
    Carver
  8. Danila
    Danila
  9. Fornier
    Fornier
  10. Hudis
    Hudis

Groups

  1. Department of Medicine (23)
  2. Genitourinary Oncology Service (23)
  3. Solid Tumor Oncology Division (23)
  4. Hematologic Malignancies, Division of (3)
  5. Nursing (2)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  7. Breast Medicine Service (1)
  8. Center for Pancreatic Cancer Research (1)
  9. Gastrointestinal Oncology Service (1)
  10. Radiation Oncology, Department of (1)
Search Within
  1. "Dana Rathkopf"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (6)
Groups
  1. Department of Medicine (23)
  2. Genitourinary Oncology Service (23)
  3. Solid Tumor Oncology Division (23)
  4. Hematologic Malignancies, Division of (3)
  5. Nursing (2)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)

More Groups

People
  1. Dana Rathkopf (23)
  2. Howard Scher (7)
  3. Susan Slovin (3)
  4. Brooke Decker (2)
  5. Michael Morris (2)
  6. Wassim Abida (2)

More People

Years
  1. 2023 (3)
  2. 2022 (1)
  3. 2021 (3)
  4. 2019 (1)
  5. 2018 (2)
  6. 2017 (1)

More Years

Publications
  1. Annals of Oncology (23)

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE
    Meeting Abstract

    Chi, K. N. N.; Castro, E.; Attard, G.; Smith, M. R.; Sandhu, S. K.; Efstathiou, E.; Roubaud, G.; Small, E. J. J.; Gomes, A. J. P. D. S; Rathkopf, D.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
    Meeting Abstract

    Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S; Roubaud, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: Second interim analysis of the randomized phase III MAGNITUDE trial
    Journal Article

    Chi, K. N.; Sandhu, S.; Smith, M. R.; Attard, G.; Saad, M.; Olmos, D.; Castro, E.; Roubaud, G.; Pereira de Santana Gomes, A. J.; Small, E. J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of sacituzumab govitecan (SG) in patients (Pts) with metastatic castration resistant prostate cancer (mCRPC) progressing on androgen receptor signaling inhibitors (ARSI)
    Meeting Abstract

    Lang, J.; Tagawa, S. T.; Slovin, S.; Emamekhoo, H.; Rathkopf, D.; Abida, W.; Autio, K.; Xiao, H.; Molina, A. M.; Eickhoff, J.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Oudard, S. M.; Bevans, K. B.; Attard, G.; Efstathiou, E.; Flaig, T. W.; Franke, F. A.; Goodman, O. B. Jr; De Giorgi, U.; Pieczonka, C. M.; Yeruva, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)
    Meeting Abstract

    Chi, K. N.; Rathkopf, D.; Attard, G.; Smith, M. R.; Efstathiou, E.; Olmos, D.; Small, E. J.; Lee, J. Y.; Sieber, P.; Dunshee, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • AZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
    Meeting Abstract

    de Bono, J. S.; Hansen, A.; Choudhury, A. D.; Cook, N.; Heath, E. I.; Higano, C.; Linch, M.; Martin-Liberal, J.; Rathkopf, D. E.; Wisinski, K. B.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Naming disease states for clinical utility in prostate cancer: A rose by any other name might not smell as sweet
    Journal Article

    Armstrong, A. J.; Antonarakis, E. S.; Taplin, M. E.; Kelly, W. K.; Beltran, H.; Fizazi, K.; Dahut, W. L.; Shore, N.; Slovin, S.; George, D.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save